MedTrace Logo

Evaluation of Filler Injection for Chin Profile Enhancement

NCT07777926 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-08-20

No results posted yet for this study

Summary

The goal of this prospective study is to analyze volumetric changes in the lower face after hyaluronic acid filler injections over 90 days.

The primary aim of the study is to quantify volume change of the lower face rea over time after injection of filler. The secondary aim is to collect patient related outcomes (PROs) via FACE-Q.

Participants will receive hyaluronic acid filler injections (Restylane Lyft(for contouring of the chin. Each patient will receive FDA approved dosages of filler to the lower face region to treat chin regression or chin contouring, as per FDA approved indications.

Prior to injections patients will be imaged with 3-dimensional photogrammetry. Subjects will return post-injection in 2 weeks, 1 month, and 3 moths for re-imaging.

Conditions

  • Chin Regression
  • Chin Asymmetry
  • Jawline Contour Deficit

Interventions

DRUG

HA Filler

Patients will receive FDA approved dosages of filler to the lower face region to treat chin regression or contour the chin, as per FDA approved indications. Patients are limited to the maximum recommended injected dose per patient for the initial and re-treatment (touch-up) injections of 4 mL. The injected volume per injection site should not exceed 2mL, the maximum volume studied and established by the manufacturer. Prior to injections, patients will be imaged with 3-dimensional photogrammetry and take a validated survey questionnaire (FACE-Q). Subjects will return post-injection in 2 weeks, 1 month, and 3 months for re-imaging and FACE-Q survey completion.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2026-12-01
Completion
2026-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07777926 on ClinicalTrials.gov